Quantcast
Home > Quotes > ACHN
ACHN

Achillion Pharmaceuticals, Inc. Common Stock (ACHN) Quote & Summary Data

$3
*  
0.10
3.45%
Get ACHN Alerts
*Delayed - data as of Nov. 21, 2018 11:11 ET  -  Find a broker to begin trading ACHN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ACHN Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2.99 / $ 3
1 Year Target
5
Today's High / Low
$ 3.03 / $ 2.89
Share Volume
503,769
50 Day Avg. Daily Volume
1,508,955
Previous Close
$ 2.90
52 Week High / Low
$ 4.34 / $ 2.33
Market Cap
415,848,510
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.56
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.04

Intraday Chart

Shares Traded

Share Volume:
503,769
50 Day Avg. Daily Volume:
1,508,955

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.56

Trading Range

The current last sale of $3 is 28.76% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 3.03 $ 4.34
 Low: $ 2.89 $ 2.33

Company Description (as filed with the SEC)

We are a science-driven, patient-focused biopharmaceutical company seeking to leverage our believed strengths across the continuum from discovery through commercialization by discovering and developing small molecule therapeutics to meet the needs of patients with complement-mediated diseases. We have discovered and developed our complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is a part of the human innate immune system and is believed to be comprised of three pathways: the alternative pathway, the lectin pathway and the classical pathway. We are advancing novel small molecules from this platform which target complement factor D, an essential protein within the amplification loop of the alternative pathway.  ... More ...  


Risk Grade

Where does ACHN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.89
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x